MMP-TIMP Profiling for Post-MI Left Ventricular Dilation Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack practicality for identifying patients at risk for developing post-myocardial infarction (MI) left ventricular dilation (LVD) and understanding the underlying mechanisms contributing to this condition.
Innovation Solution
A method involving the identification of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in body fluids to predict the likelihood of left ventricular dilation post-MI, utilizing plasma profiles and echocardiography for validation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional clinical methods are used to monitor post-MI patients, then standard care can be provided, but the ability to identify patients at risk for LV dilation is insufficient
Solution Approach 1:
The patent measures multiple MMP and TIMP parameters simultaneously to identify patients at risk for LV dilation. By monitoring the levels and ratios of these proteolytic enzymes (MMP-1, MMP-2, MMP-9, TIMP-1, TIMP-2, TIMP-3), the method transforms traditional single-parameter monitoring into multi-parameter profiling, thereby improving risk identification accuracy without requiring complex structural changes to the diagnostic approach
Solution Approach 2:
The MMP/TIMP profiling method serves multiple functions: it identifies patients at risk for LV dilation, provides prognostic information about remodeling progression, and potentially guides therapeutic decisions. This multi-functional biomarker panel replaces or supplements multiple separate assessments, improving comprehensive patient evaluation while maintaining practical clinical workflow
2Loss of time
If MMP and TIMP profiling is implemented, then early identification of at-risk patients is achieved, but the complexity of the diagnostic method increases
Solution Approach 1:
The patent measures MMP and TIMP levels early in the post-MI period (acute and subacute phases) to predict future LV dilation risk before structural changes become evident on imaging. This preliminary biomarker assessment allows clinicians to identify at-risk patients proactively, enabling early intervention before significant remodeling occurs, thereby reducing the time lag between risk development and detection
Solution Approach 2:
The method combines measurement of multiple related biomarkers (MMPs and TIMPs) into a single integrated profiling approach. By measuring these enzymes together and analyzing their ratios (such as MMP-2/TIMP-2 and MMP-9/TIMP-1), the patent consolidates what could be multiple separate tests into a coordinated diagnostic panel, improving efficiency while managing complexity through systematic analysis
3Loss of information
If detailed MMP and TIMP profiles are measured, then prognostic information on remodeling is improved, but the cost and complexity of testing increase
Solution Approach 1:
The patent extracts and measures specific proteolytic enzymes (MMPs and TIMPs) from the complex mixture of proteins in blood or serum. By focusing on this targeted subset of biomarkers known to be involved in extracellular matrix remodeling, the method obtains comprehensive prognostic information about LV remodeling without requiring analysis of all plasma proteins, thereby balancing information completeness with testing feasibility
Solution Approach 2:
The patent monitors changes in MMP and TIMP levels over time (longitudinal profiling) to track the progression or regression of remodeling processes. By measuring these parameters at multiple time points post-MI and analyzing their temporal patterns and ratios, the method provides dynamic prognostic information about individual patient trajectories, enabling personalized risk assessment without requiring excessive resource investment at each time point
Data Source
AI summary
Disclosed herein are methods of detecting or predicting diastolic heart failure in a subject, comprising identifying a profile of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) from a body fluid of the subject that is associated herein with the existence of likely development of left ventricular dilation (LVD).